GlassScriptPhysician profile
Joseph A Bruno
NPI 1487658746
$9,605.28
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,050 · 2020: $2,369 · 2021: $2,594 · 2022: $1,810 · 2023: $608 · 2024: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,612.48 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $896.16 | 2019-2022 | |
| Amgen INC. | $885.80 | 2019-2024 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.49 | 2019-2024 | Tradjenta, Jardiance |
| Janssen Pharmaceuticals, INC | $533.87 | 2019-2022 | |
| Abbvie INC. | $446.92 | 2019-2023 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $441.66 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $390.34 | 2019-2023 | |
| Amarin Pharma, INC. | $385.95 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $356.80 | 2019-2022 | |
| Lilly USA, LLC | $323.91 | 2020-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $273.89 | 2019-2024 | Capvaxive |
| Kowa Pharmaceuticals America, INC. | $256.98 | 2020-2022 | |
| Grifols USA, LLC | $224.85 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $219.00 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.